Coeptis Therapeutics Holdings, Inc. (COEP) Stock

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Coeptis Therapeutics Holdings, Inc. is led by CEO David Mehalick, employs 5 people, headquartered in US, publicly traded since 2020.

Coeptis Therapeutics Holdings, Inc. (COEP) stock trades at $10.99 with a market capitalization of $38.62M. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.45, reflecting a net loss over the last twelve months, price-to-book of 3.18, price-to-sales of 27.31. Over the past 52 weeks the stock has ranged between $6.80 and $21.41, and currently trades 48.7% below its 52-week high.

On profitability, Coeptis Therapeutics Holdings, Inc. generates a return on equity (ROE) of -83.85% (negative, reflecting a net loss), return on capital employed of -71.80%, an operating margin of -912.42%, a net profit margin of -839.69%.

Official website: coeptistx.com

Coeptis Therapeutics Holdings, Inc. by the numbers, 2004–2025

Between 2004 and 2025 Coeptis Therapeutics Holdings, Inc. reported revenue of $0 rising to $1.0M. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-12.0M.

The most recent net margin is -839.69%. On a trailing twelve-month basis to Mar '26, revenue is $1.0M and net profit $-13.0M.

Borrowings stand at $0, cash on hand is $5.3M, cash from operations was $-9.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged -512.5% over five years, and was -70.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Coeptis Therapeutics Holdings, Inc. (COEP) — frequently asked questions